FDA Approves New Therapy For Advanced Breast Cancer

#BreastCancer #FDA #CancerResearch #HealthNews

Breaking: FDA approves Eli Lilly’s Inluriyo (imlunestrant) for advanced/metastatic breast cancer with ER-1 mutations. Phase 3 trial shows 5.5 mo median progression-free survival vs 3.8 mo. Oral therapy, ~$22,500/28 days. A hopeful step forward!